NCT03367689
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes: HR+ & HER2-negative patients are only eligible for second stage of study
Exclusions: Deleterious germline BRCA1/2 mutation; Symptomatic uncontrolled brain metastases
https://ClinicalTrials.gov/show/NCT03367689